CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Appoints Monica Tellado as President, Emerging Markets

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

26 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

25 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

02 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

17 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

27 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

03 May 2023 15:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 Apr 2023 15:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Final Results of Tender Offer

05 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Results of Tender Offer

03 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

28 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call

14 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Provides Miricorilant Clinical Development Update

08 Dec 2022 07:00:02 By Nasdaq GlobeNewswire

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

08 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

03 Nov 2022 15:05:02 By Nasdaq GlobeNewswire